{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:03:37Z","timestamp":1781777017347,"version":"3.54.5"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,5,4]],"date-time":"2019-05-04T00:00:00Z","timestamp":1556928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11011-019-00416-1","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T13:14:56Z","timestamp":1557148496000},"page":"1191-1199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats"],"prefix":"10.1007","volume":"34","author":[{"given":"Sadaf","family":"Naeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahila","family":"Najam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira Saeed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talat","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Sikandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,4]]},"reference":[{"key":"416_CR1","doi-asserted-by":"crossref","unstructured":"Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM (2012) CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33:430.e1\u2013430.e3","DOI":"10.1016\/j.neurobiolaging.2010.12.001"},{"issue":"6","key":"416_CR2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3390\/ph3061949","volume":"3","author":"MA Ajmone-Cat","year":"2010","unstructured":"Ajmone-Cat MA, Bernardo A, Greco A, Minghetti L (2010) Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions. Pharmaceuticals 3(6):1949\u20131964","journal-title":"Pharmaceuticals"},{"issue":"6","key":"416_CR3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10787-013-0181-9","volume":"21","author":"MM Al-Amin","year":"2013","unstructured":"Al-Amin MM, Uddin MM, Rahman MM, Reza HM, Rana MS (2013) Effect of diclofenac and antidepressants on the inflammatory response in astrocyte cell culture. Inflammopharmacology 21(6):421\u2013425","journal-title":"Inflammopharmacology"},{"key":"416_CR4","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1046\/j.1471-4159.2001.00205.x","volume":"76","author":"M Asanuma","year":"2001","unstructured":"Asanuma M, Miyazaki I, Kohno M, Ogawa N (2001) Neuroprotective effects on non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 76:1895\u20131904","journal-title":"J Neurochem"},{"key":"416_CR5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fnagi.2010.00035","volume":"2","author":"BB Bendlin","year":"2010","unstructured":"Bendlin BB, Newman LM, Ries ML, Puglielli L, Carlsson CM, Sager MA, Johnson SC (2010) NSAIDs may protect against age-related brain atrophy. Front Aging Neurosci 2:35","journal-title":"Front Aging Neurosci"},{"key":"416_CR6","first-page":"859","volume":"43","author":"P Bigoniya","year":"2005","unstructured":"Bigoniya P, Rana AC (2005) Psychopharmacological profile of hydro-alcoholic extract of euphorbia Neriifolia leaves in mice and rats. Indian J Exp Biol 43:859\u2013862","journal-title":"Indian J Exp Biol"},{"issue":"1\u20133","key":"416_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejphar.2006.09.010","volume":"552","author":"M Bishnoi","year":"2006","unstructured":"Bishnoi M, Chopra K, Kulkarni SK (2006) Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 552(1\u20133):55\u201366","journal-title":"Eur J Pharmacol"},{"key":"416_CR8","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/bonekey.2015.101","volume":"4","author":"A Bonetto","year":"2015","unstructured":"Bonetto A, Andersson DC, Waning DL (2015) Assessment of muscle mass and strength in mice. Bonekey Rep 4:732","journal-title":"Bonekey Rep"},{"key":"416_CR9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.biopsych.2005.08.009","volume":"59","author":"TA Cairo","year":"2006","unstructured":"Cairo TA, Woodward TS, Ngan ET (2006) (2006). Decreased encoding efficiency in schizophrenia. Biol Psychiatry 59:740\u2013746","journal-title":"Biol Psychiatry"},{"issue":"2","key":"416_CR10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12640-012-9342-7","volume":"23","author":"AR Carta","year":"2013","unstructured":"Carta AR, Pisanu A (2013) Modulating microglia activity with PPAR-\u03b3 agonists: a promising therapy for Parkinson's disease? Neurotox Res 23(2):112\u2013123","journal-title":"Neurotox Res"},{"key":"416_CR11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3940(00)01294-5","volume":"289","author":"D Casper","year":"2000","unstructured":"Casper D, Yaparpalvi U, Rempel N, Werner P (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 289:201\u201320410","journal-title":"Neurosci Lett"},{"key":"416_CR12","first-page":"19","volume":"6","author":"T Chen","year":"2010","unstructured":"Chen T, Koga K, Li XY, Zhuo M (2010) Spinal microglial motility is independent of neuronal activity and plasticity in adult mice. Mol Pain 6:19","journal-title":"Mol Pain"},{"key":"416_CR13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tips.2009.01.002","volume":"30","author":"SH Choi","year":"2009","unstructured":"Choi SH, Aid S, Bosetti F (2009) The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 30:174\u2013181","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"416_CR14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.12059","volume":"124","author":"S-H Choi","year":"2013","unstructured":"Choi S-H, Aid S, Caracciolo L, Sakura Minami S, Niikura T, Matsuoka Y, Turner RS, Mattson MP, Bosetti F (2013) Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer\u2019s disease. J Neurochem 124(1):59\u201368","journal-title":"J Neurochem"},{"key":"416_CR15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1523\/JNEUROSCI.20-02-00558.2000","volume":"20","author":"CK Combs","year":"2000","unstructured":"Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer\u2019s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20:558\u2013567","journal-title":"J Neurosci"},{"key":"416_CR16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0899-9007(96)00000-8","volume":"12","author":"EM Conner","year":"1996","unstructured":"Conner EM, Grisham MB (1996) Inflammation, free radicals an antioxidants. Nutrition 12:274\u2013277","journal-title":"Nutrition"},{"key":"416_CR17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer W, Przedborski S (2003) Parkinson\u2019s disease: mechanisms and models. Neuron 39:889\u2013909","journal-title":"Neuron"},{"key":"416_CR18","doi-asserted-by":"crossref","unstructured":"De La Garza R, Asnis GM (2003). The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus Brain Res 4;977(1):70-9","DOI":"10.1016\/S0006-8993(03)02757-4"},{"issue":"1","key":"416_CR19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0166-4328(03)00211-0","volume":"149","author":"R De La Garza","year":"2004","unstructured":"De La Garza R, Fabrizio KR, Radoi GE, Vlad T, Asnis GM (2004) (2004). The non-steroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysaccharide-induced alterations to reward behavior and corticosterone release. Behav Brain Res 149(1):77\u201385","journal-title":"Behav Brain Res"},{"issue":"2","key":"416_CR20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00213-004-2053-x","volume":"179","author":"R De La Garza","year":"2005","unstructured":"De La Garza R, Asnis GM, Fabrizio KR, Pedrosa E (2005) Acute diclofenac treatment attenuates lipopolysaccharide-induced alterations to basic reward behavior and HPA axis activation in rats. Psychopharmacology (Berl) 179(2):356\u2013365","journal-title":"Psychopharmacology (Berl)"},{"key":"416_CR21","doi-asserted-by":"crossref","unstructured":"Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug-induced oxidative stress and toxicity. J Toxicol 2012, Article ID 645460:13","DOI":"10.1155\/2012\/645460"},{"issue":"3","key":"416_CR22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/eji.201445222","volume":"45","author":"F D\u00edaz-Gonz\u00e1lez","year":"2015","unstructured":"D\u00edaz-Gonz\u00e1lez F, S\u00e1nchez-Madrid F (2015) NSAIDs: learning new tricks from old drugs. Eur J Immunol 45(3):679\u2013686","journal-title":"Eur J Immunol"},{"key":"416_CR23","doi-asserted-by":"crossref","first-page":"d198","DOI":"10.1136\/bmj.d198","volume":"342","author":"JA Driver","year":"2011","unstructured":"Driver JA, Logroscino G, Lu L, Gaziano JM, Kurth T (2011) Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. BMJ 342:d198","journal-title":"BMJ"},{"key":"416_CR24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/187152710791292639","volume":"9","author":"F Episcopo","year":"2010","unstructured":"Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B (2010) Glia as a turning point in the therapeutic strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 9:349\u2013372","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"416_CR25","first-page":"679","volume-title":"Parkinsonism in Merritt\u2019s neurology","author":"S Fahn","year":"2000","unstructured":"Fahn S, Przedborski S (2000) Parkinsonism. In: Rowland LP (ed) Parkinsonism in Merritt\u2019s neurology. Lippincott, Williams & Wilkins, New York, pp 679\u2013693"},{"issue":"15","key":"416_CR26","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1097\/00001756-200310270-00009","volume":"14","author":"Z Feng","year":"2003","unstructured":"Feng Z, Li D, Fung PCW, Pei Z, Ramsden DB, Ho S (2003) COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. NeuroReport 14(15):1927\u20131929","journal-title":"NeuroReport"},{"key":"416_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005072-199603000-00001","volume":"55","author":"LS Forno","year":"1996","unstructured":"Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259\u2013272","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"416_CR28","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"CK Glass","year":"2010","unstructured":"Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140(6):918\u2013934","journal-title":"Cell"},{"key":"416_CR29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/ajcn\/83.2.470S","volume":"83","author":"WS Griffin","year":"2006","unstructured":"Griffin WS (2006) (2006). Inflammation and neurodegenerative diseases. Am J Clin Nutr 83:470\u2013474","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"416_CR30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1476-5381.1969.tb08009.x","volume":"36","author":"HC Guldberg","year":"1969","unstructured":"Guldberg HC, Yates CM (1969) Effects of chlorpromazine on the metabolism of catecholamines in dog brain. Br J Pharmacol 36(3):535\u2013548","journal-title":"Br J Pharmacol"},{"issue":"12","key":"416_CR31","first-page":"847","volume":"54","author":"NM Hassanein","year":"2004","unstructured":"Hassanein NM, Hasan WA, Hamed MR (2004) (2004). Effects of diclofenac, piroxicam and alpha-tocopherol on monoaminelymphopoietic interfacing in mice. Arzneimittelforschung. 54(12):847\u2013856","journal-title":"Arzneimittelforschung."},{"issue":"4","key":"416_CR32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/157015912804499483","volume":"10","author":"MS Hernandes","year":"2012","unstructured":"Hernandes MS, Britto LRG (2012) NADPH Oxidase and Neurodegeneration. Curr Neuropharmacol 10(4):321\u2013327","journal-title":"Curr Neuropharmacol"},{"key":"416_CR33","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.2_Suppl_2.S2","volume":"51","author":"O Homykiewicz","year":"1998","unstructured":"Homykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51:S2\u2013S9","journal-title":"Neurology"},{"key":"416_CR34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1568007054038201","volume":"4","author":"JJ Hoozemans","year":"2005","unstructured":"Hoozemans JJ, O'Banion MK (2005) The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 4:307\u2013315","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"416_CR35","first-page":"CD006378","volume":"2","author":"D Jaturapatporn","year":"2012","unstructured":"Jaturapatporn D, Isaac MG, Mc-Cleery J, Tabet N (2012) Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease. Cochrane Database Syst Rev 2:CD006378","journal-title":"Cochrane Database Syst Rev"},{"key":"416_CR36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jchemneu.2017.08.006","volume":"87","author":"AA Kaplan","year":"2017","unstructured":"Kaplan AA, Yurt KK, Deniz OG, Altun G (2017) Peripheral nerve and diclofenac sodium: molecular and clinical approaches. J Chem Neuroanat 87:2\u201311","journal-title":"J Chem Neuroanat"},{"key":"416_CR37","unstructured":"Karch AM (2009). Focus on nursing pharmacology, 5thed. Philadelphia: Lippincott Williams & Wilkins; publishing CO, New York, pp. 548\u2013551"},{"issue":"5","key":"416_CR38","first-page":"1525","volume":"29","author":"H Khatoon","year":"2016","unstructured":"Khatoon H, Najam R, Mirza T, Sikandar B (2016) Beneficial anti-parkinson effects of camel milk in Chlorpromazine- induced animal model: Behavioural and histopathological study. Pak J Pharm Sci 29(5):1525\u20131529","journal-title":"Pak J Pharm Sci"},{"key":"416_CR39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00441-004-0975-6","volume":"318","author":"T Klockgether","year":"2004","unstructured":"Klockgether T (2004) Parkinson\u2019s disease:clinical aspects. Cell Tissue Res 318:115\u2013120","journal-title":"Cell Tissue Res"},{"issue":"6","key":"416_CR40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00210-014-0966-4","volume":"387","author":"M Ko\u0142aczkowski","year":"2014","unstructured":"Ko\u0142aczkowski M, Mierzejewski P, Bienkowski P, Weso\u0142owska A, Newman-Tancredi A (2014) Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. NaunynSchmiedeberg\u2019s. Arch Pharmacol 387(6):545\u2013557","journal-title":"Arch Pharmacol"},{"key":"416_CR41","first-page":"732806","volume":"2010","author":"DL Krause","year":"2010","unstructured":"Krause DL, M\u00fcller N (2010) Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Int J Alzheimers Dis 2010:732806","journal-title":"Int J Alzheimers Dis"},{"key":"416_CR42","unstructured":"Kulkarni SK (2007). Handbook of experimental pharmacology: 3 rd revised ed. New Delhi: VallabhPrakashan; p. 135-7"},{"key":"416_CR43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/187152710791292639","volume":"9","author":"F L\u2019 Episcopo","year":"2010","unstructured":"L\u2019 Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B (2010) Glia as a turning point in the therapeutic strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 9:349\u2013372","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"416_CR44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nurt.2008.05.003","volume":"5","author":"G Landreth","year":"2008","unstructured":"Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPAR gamma agonists as therapeutics for the treatment of Alzheimer\u2019s disease. Neurotherapeutics 5:481\u2013489","journal-title":"Neurotherapeutics"},{"issue":"4","key":"416_CR45","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F","volume":"46","author":"JW Langston","year":"1999","unstructured":"Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46(4):598\u2013605","journal-title":"Ann Neurol"},{"issue":"4","key":"416_CR46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195521","volume":"13","author":"T Makunts","year":"2018","unstructured":"Makunts T, Cohen IV, Lee KC, Abagyan R (2018) Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain. PLoS One 13(4):e0195521","journal-title":"PLoS One"},{"key":"416_CR47","unstructured":"Marsden CD, Calne DB (1994) Recent development in parkinson's disease. Florham Park, Macmillan; Health Care Information, pp 153\u2013164"},{"issue":"2","key":"416_CR48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1471-4159.2007.05141.x","volume":"105","author":"E Milusheva","year":"2008","unstructured":"Milusheva E, Baranyi M, Kittel A, Fekete A, Zelles T, Vizi ES, Sperl\u00e1gh B (2008) Modulation of dopaminergic neurotransmission in rat striatum upon in vitro and in vivo diclofenac treatment. J Neurochem 105(2):360\u2013368","journal-title":"J Neurochem"},{"issue":"1","key":"416_CR49","doi-asserted-by":"crossref","first-page":"a009381","DOI":"10.1101\/cshperspect.a009381","volume":"2","author":"RL Mosley","year":"2012","unstructured":"Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflammation and adaptive immunity in Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2(1):a009381","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"416_CR50","first-page":"801","volume":"30","author":"S Naeem","year":"2017","unstructured":"Naeem S, Ikram R, Khan SS, Rao SS (2017) NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine. Pak J Pharm Sci 30(3):801\u2013808","journal-title":"Pak J Pharm Sci"},{"key":"416_CR51","first-page":"480","volume":"126","author":"V Nair","year":"2007","unstructured":"Nair V, Arjuman A, Dorababu P, Gopalakrishna HN, Rao UC, Mohan L (2007) Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice. Indian J Med Res 126:480\u2013484","journal-title":"Indian J Med Res"},{"issue":"6","key":"416_CR52","first-page":"851","volume":"11","author":"F Ng","year":"2008","unstructured":"Ng F, Berk M, Dean O, Bush AI (2008) 2008. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11(6):851\u2013876","journal-title":"Int J Neuropsychopharmacol"},{"key":"416_CR53","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11095-006-9905-5","volume":"23","author":"JM Parepally","year":"2006","unstructured":"Parepally JM, Mandula H, Smith QR (2006) Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res 23:873\u2013881","journal-title":"Pharm Res"},{"key":"416_CR54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0022-3956(02)00048-1","volume":"37","author":"V Parikh","year":"2003","unstructured":"Parikh V, Khan MM, Mahadik SP (2003) Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 37:43\u201351","journal-title":"J Psychiatr Res"},{"issue":"12","key":"416_CR55","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1590\/S0100-879X2005001200015","volume":"38","author":"JG Pires","year":"2005","unstructured":"Pires JG, Bonikovski V, Futuro-Neto HA (2005) Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res 38(12):1867\u20131872 Epub","journal-title":"Braz J Med Biol Res"},{"issue":"5","key":"416_CR56","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2174\/187152711796235014","volume":"10","author":"V Pizza","year":"2011","unstructured":"Pizza V, Agresta A, D'Acunto CW, Festa M, Capasso A (2011) Neuroinflamm-aging and neurodegenerative diseases: an overview. CNS Neurol Disord Drug Targets 10(5):621\u2013634","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"416_CR57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.immunol.021908.132528","volume":"27","author":"RM Ransohoff","year":"2009","unstructured":"Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119\u2013145","journal-title":"Annu Rev Immunol"},{"key":"416_CR58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","volume":"62","author":"SA Reines","year":"2004","unstructured":"Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC (2004) Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62:66\u201371","journal-title":"Neurology"},{"issue":"2","key":"416_CR59","first-page":"393","volume":"31","author":"B Riaz","year":"2018","unstructured":"Riaz B, Ikram R, Sikandar B (2018 Mar) 2018. Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease. Pak J Pharm Sci 31(2):393\u2013397","journal-title":"Pak J Pharm Sci"},{"issue":"2","key":"416_CR60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0006-8993(02)04174-4","volume":"966","author":"K Sairam","year":"2003","unstructured":"Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966(2):245\u2013252","journal-title":"Brain Res"},{"key":"416_CR61","unstructured":"Sandhu K, Rana A (2013). Evaluation of antiparkinson\u2019s activity of Nigella Sativa seeds in chlorpromazine induced experimental animal model . Academic Sciences: Aug 201, Vol 5, Suppl 3, 0975-1491"},{"issue":"3","key":"416_CR62","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2478\/intox-2013-0020","volume":"6","author":"N Sestakova","year":"2013","unstructured":"Sestakova N, Puzserova A, Kluknavsky M, Bernatova I (2013) Determination of motor activity and anxiety-related behaviour in rodents: methodological aspects and role of nitric oxide. Interdiscip Toxicol 6(3):126\u2013135","journal-title":"Interdiscip Toxicol"},{"key":"416_CR63","unstructured":"Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y (2000) Action of adenosine A2A receptor antagonist KW-6002 on drug induced catalepsy and hypokinesia caused by reserpine. Psychopharmacology 1324"},{"key":"416_CR64","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S1734-1140(13)71480-4","volume":"65","author":"M Swiatkiewicz","year":"2013","unstructured":"Swiatkiewicz M, Zaremba M, Joniec I, Cztonkowski A, Kurkowska-Jastrzebska I (2013) Potential neuroprotective effect of ibuprofen, insight from the mice model of Parkinson disease. Pharmacol Rep 65:1227\u20131236 Issue 1734-1140","journal-title":"Pharmacol Rep"},{"key":"416_CR65","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s002130000376","volume":"151","author":"P Taepavarapruk","year":"2000","unstructured":"Taepavarapruk P, Floresco SB, Phillips AG (2000) Hyperloco-motion and increased dopamine efflux in the rat nucleus accumbens evoked by electrical stimulation of the ventral subiculum: role of ionotropic glutamate and dopamineD1 receptors. Psychopharmacology (Berlin) 151:242\u2013251","journal-title":"Psychopharmacology (Berlin)"},{"key":"416_CR66","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.brainres.2009.05.016","volume":"1279","author":"E Takahashi","year":"2009","unstructured":"Takahashi E, Niimi K, Itakura C (2009) Motor coordination impairment in aged heterozygous rolling Nagoya, Cav2.1 mutant mice. Brain Res 1279:50\u201357","journal-title":"Brain Res"},{"issue":"2","key":"416_CR67","first-page":"23","volume":"11","author":"S Takween","year":"1998","unstructured":"Takween S, Ahmed SP, Haider S, Haleem DJ (1998) Effect of chlorpromazine on brain biogenic amines in normal and hyperglycemic state. Pak J Pharm Sci 11(2):23\u201329","journal-title":"Pak J Pharm Sci"},{"issue":"3","key":"416_CR68","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","volume":"37","author":"MG Tansey","year":"2009","unstructured":"Tansey MG, Goldberg MS (2009) Neuroinflammation in Parkinson\u2019s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510\u2013518","journal-title":"Neurobiol Dis"},{"issue":"4","key":"416_CR69","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.neuroscience.2008.08.030","volume":"156","author":"AV Terry","year":"2008","unstructured":"Terry AV, Warner SE, Vandenhuerk L, Pillai A, Mahadik SP, Zhang G, Bartlett MG (2008) Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience 156(4):1005\u20131016","journal-title":"Neuroscience"},{"key":"416_CR70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jchemneu.2017.03.003","volume":"87","author":"M Terzi","year":"2018","unstructured":"Terzi M, Altun G, \u015een S, Kocaman A, Kaplan AA, Yurt KK, Kaplan S (2018) The use of non-steroidal anti-inflammatory drugs in neurological diseases. J Chem Neuroanat 87:12\u201324","journal-title":"J Chem Neuroanat"},{"key":"416_CR71","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mds.20856","volume":"21","author":"TG Ton","year":"2006","unstructured":"Ton TG, Heckbert SR, Longstreth WT et al (2006) Nonsteroidal anti-inflammatory drugs and risk of Parkinson\u2019s disease. Mov Disord 21:964\u2013969","journal-title":"Mov Disord"},{"key":"416_CR72","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1096\/fj.04-3620rev","volume":"19","author":"KP Townsend","year":"2005","unstructured":"Townsend KP, Pratico D (2005) Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 19:1592\u20131601","journal-title":"FASEB J"},{"key":"416_CR73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jnr.10281","volume":"69","author":"CG Wakade","year":"2002","unstructured":"Wakade CG, Mahadik SP, Waller JL, Chiu FC (2002) Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 69:72\u201379","journal-title":"J Neurosci Res"},{"issue":"4","key":"416_CR74","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/157015907782793667","volume":"5","author":"D Walker","year":"2007","unstructured":"Walker D, Lue L-F (2007) Anti-inflammatory and immune therapy for Alzheimer\u2019s disease: current status and future directions. Curr Neuropharmacol 5(4):232\u2013243","journal-title":"Curr Neuropharmacol"},{"key":"416_CR75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener 4:19","journal-title":"Transl Neurodegener"},{"issue":"8","key":"416_CR76","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bjp.0707167","volume":"150","author":"PS Whitton","year":"2007","unstructured":"Whitton PS (2007) Inflammation as a causative factor in the etiology of Parkinson's disease. Br J Pharmacol 150(8):963\u2013976","journal-title":"Br J Pharmacol"},{"issue":"2","key":"416_CR77","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00311389","volume":"84","author":"T Yamada","year":"1992","unstructured":"Yamada T, Kawamata T, Walker DG, McGeer PL (1992) Vimentin immunoreactivity in normal and pathological human brain tissue. Acta Neuropathol 84(2):157\u2013162","journal-title":"Acta Neuropathol"},{"issue":"6","key":"416_CR78","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","volume":"19","author":"W Zhang","year":"2005","unstructured":"Zhang W, Wang T, Pei Z et al (2005) Aggregated \u03b1-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19(6):533\u2013542","journal-title":"FASEB J"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-019-00416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-019-00416-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-019-00416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T23:08:34Z","timestamp":1588460914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-019-00416-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,4]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s11011-019-00416-1","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,4]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No conflict of interest associated with this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}